Dapagliflozin and Metformin in T2D: Three Important Indian Evidences Revisited- Dr Semanti Chakraborty Written By Dr. Semanti Chakraborty10 Jun 2026 11:09 AM ISTIndia's Type 2 diabetes(T2D) prevalence is increasing, with over half of affected individuals remaining undiagnosed. More than 70% of Indian T2D...
Orbit of Care in Indian T2D with CV Risk: Practice Update & Spotlight on Smart Application of Dapagliflozin & Sitagliptin FDC Written By Dr Manoj Chawla4 Jun 2026 10:56 AM ISTIn India, type 2 diabetes(T2D) clusters with cardiovascular risk and earlier age than in Western populations, mainly driven by visceral adiposity...
Dapagliflozin-Metformin in Obese T2D After GLP-RA: Assessing Newer Possibilities- Dr Bharat Saboo Written By Dr Bharat Saboo26 May 2026 10:37 AM ISTGlobally and in India, T2DM prevalence continues to rise, with obesity as one of its most important clinical drivers, reported in nearly 60-90% of...
Metformin: Anchor in the Metabolic Journey of Prediabetes Care- Dr Dwaipayan Deb Written By Dr Dwaipayan Deb29 April 2026 11:24 AM ISTPrediabetes affects 634.8 million adults globally, i.e., approximately 12% of the adult population (IDF, 2025), with 30.4% prevalence among Indian...
Diabetes study reveals previously overlooked genes tied to disease, pointing to new therapies Written By Dr. Kamal Kant Kohli18 April 2026 9:00 AM ISTDozens of unexpected genes are strongly linked to type 2 diabetes, new research from The Jackson Laboratory (JAX) shows. The findings, based on a new...
Integrating Dapagliflozin and Sitagliptin FDC for Optimizing Outcomes in Type-2 Diabetes with Cardiometabolic-Based Chronic Disease (CMBCD) patients - Dr Kaushik Biswas Written By Dr. Kaushik Biswas28 March 2026 10:27 AM ISTIntroduction India's T2D population carries a substantial burden-nearly two-thirds of individuals with T2D are overweight or obese, indicating a...
ACC/AHA Release 2026 Guideline on Dyslipidemia Management: Earlier Treatment, New Risk Tools, and Lower LDL Targets Recommended Written By Aditi Dhingra16 March 2026 11:52 AM ISTThe American College of Cardiology (ACC) and the American Heart Association (AHA) have released the 2026 ACC/AHA Guideline on the Management of...
T2D and CKD Risk: Can Weight Loss Alter Kidney Outcomes? Written By Dr. Kamal Kant Kohli16 March 2026 11:03 AM ISTType 2 diabetes mellitus (T2DM) represents a mounting global health crisis. India, home to 17.78% of the world's population, ranks second globally...
Beyond Glycaemia- Weight Reduction Is the New Additional Therapeutic Endpoint in T2D Written By Dr. Kamal Kant Kohli7 March 2026 10:59 AM ISTIndia bears a disproportionate share of the global diabetes burden, with 89.8 million adults living with T2DM against a worldwide estimate of 589...
Therapeutic Application of Empagliflozin, Sitagliptin, and Metformin for Advancing Overall Wellness in T2D: Evidence Review for Practitioners in 2025 Written By Dr. Manoj Chadha19 Feb 2026 10:35 AM ISTHyperglycemia in T2D plays a pivotal role in diabetic microvascular complications; however, reducing HbA1c offers only modest benefit in mitigating...
Aspirin Benefit for Primary Prevention in High-Risk T2D - Observational Analysis: AHA 2025 Abstract Written By Dr. Nitin Gudage17 Feb 2026 12:00 PM ISTFor years, the medical community has sought the ideal balance for aspirin in primary prevention. New evidence from the American Heart Association...
Robust Glycemic Control & Cardio-Renal Protection: Meeting the Advanced Needs of Indian Uncontrolled T2D with Empagliflozin, Sitagliptin, Metformin Written By Dr. Nilanjan Sengupta28 Jan 2026 12:45 PM ISTIndia has an estimated 90 million people living with T2D [1] amid rising obesity and doubled management costs. Uncontrolled T2DM and early-onset...
